With these considerations, and the lack of prognostic and predictive value of IHC assessed quantitative ER and PR load as shown in this review, the distinction between IHC-based luminal-A-like and luminal-B-like tumours should not be used to tailor treatment decisions for women with HR-positive stage 1–3 breast cancer. This evidence concerns the gene PGR and neoplasm.